Clinical Trial Update: Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase II trial evaluating gemcitabine plus romidepsin in relapsed/refractory peripheral T-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Romidepsin (romidepsin)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-10-10